Advertisement

Five top biotech innovators

Professional investor Dr Daniel Koller picks five innovative biotech stocks to buy now.

Each week, a professional investor tells us where he'd put his money. This week:Dr Daniel Koller, lead manager of BB Biotech.

The last decade saw biotechnology industry sales rise from $6bn to $131bn, driven principally by a new generation of discoveries enabling biotechs to bring industry-changing products to market. These technological advances and the number of new drug approvals have led to powerful growth in the number of companies making a profit. Positive data from recent clinical trials indicate that there's plenty more to come.

Advertisement - Article continues below

Why then has 2016 seen biotech stocks underperforming general equity markets by 20%? Various factors were at play, but politics has hit sentiment hard. Healthcare stocks and the drug industry, including biotech, have already endured punishment at the hands of Democratic nominee Hillary Clinton, with drug prices being a pillar of her campaign. As expectations of a Clinton victory increased in recent weeks, biotech stocks were hit once again. These discussions will continue until early 2017, when the newly elected US president announces her or his future healthcare policy plans.

But political criticism is often aimed at the list price and ignores that high growth rates are generated by volume. New drugs make it possible to treat far more patients than before, and the final level of sales is correspondingly high. Thus any discussion about the price of a drug should revolve first and foremost around its medical value or benefit to patients and society.

Advertisement - Article continues below

BB Biotech, the fund I manage, remains focused on biotech firms offering innovation that promises to improve treatment for serious diseases. Companies of particular interest include Radius Health (Nasdaq: RDUS), Cempra (Nasdaq: CEMP) and Vertex Pharmaceuticals (Nasdaq: VRTX). They have all made progress with their main drugs in development: Radius's treatment for postmenopausal women with osteoporosis is in for New Drug Application (NDA) approval in the US; Cempra submitted its NDA for a drug to treat community-acquired bacterial pneumonia; Vertex is testing a key triple combination to treat cystic fibrosis.

With one of the weakest years of results now behind us, we expect a return to growth for the sector. Product approvals and results from key clinical trials offer the potential for growth in valuations for the remaining months of 2016 and into 2017. Many large pharmaceutical and biotechnology companies are looking to mergers and acquisitions and industry consolidation, and the number of profitable biotechs is steadily growing. We are maintaining our current approach of building a portfolio of a small number of core holdings, plusmid- and small caps with the potential to grow faster than the market. Companies in their growth phase that are poised to become large caps, such asActelion(Zurich: ATLN) or Incyte (Nasdaq: INCY), are particularly attractive.

Advertisement
Advertisement

Recommended

Visit/investments/stocks-and-shares/share-tips/600641/share-tips-of-the-week
Share tips

Share tips of the week

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
17 Jan 2020
Visit/519913/share-tips-8-stocks-for-robust-returns
Share tips

Share tips: eight stocks that should deliver robust returns

Ryan Ermey of US publication Kiplinger’s Personal Finance chooses his favourite stocks for the next decade, which should be able to grow for years.
28 Dec 2019
Visit/519724/share-tips-of-the-week-166
Share tips

Share tips of the week

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
20 Dec 2019
Visit/519436/share-tips-of-the-week-165
Share tips

Share tips of the week

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
13 Dec 2019

Most Popular

Visit/economy/uk-economy/601427/covid-bounce-back-loans-and-inflation
UK Economy

What bounce back loans can tell us about how we’ll pay for all this

The government will guarantee emergency "bounce back loans" for small businesses hit by Covid-19. Inevitably, many businesses will default. And there'…
1 Jun 2020
Visit/investments/commodities/601433/commodities-possibly-the-biggest-opportunity-in-todays-markets
Commodities

This looks like the biggest opportunity in today’s markets

With low interest rates and constant money-printing, most assets have become expensive. But one major asset class hasn’t. John Stepek explains why com…
2 Jun 2020
Visit/investments/commodities/gold/601444/these-seven-charts-show-exactly-why-you-must-own-gold-today
Gold

These seven charts show exactly why you must own gold today

Covid-19 is accelerating many trends that were already in existence. The rising gold price is one such trend. These seven charts, says Dominic Frisby,…
3 Jun 2020